About Yuhan
Yuhan is a publicly listed company based in Seoul (South Korea). Yuhan Corporation is engaged in pharmaceutical and health product development. It operates on a Direct-to-Consumer (D2C) and HealthTech model. Yuhan has completed 1 acquisition, including Waratnec. Yuhan offers products and services including Rapicol Care Dry Syrup and Willopet. Its focus areas include Pharmaceuticals and Prescription Drugs.
Company details
Yuhan Corporation is involved in the development and production of pharmaceutical products and health solutions. The company operates in the healthcare sector, focusing on innovative drugs and consumer health products. Various solutions are offered, including comprehensive cold medicines and pet care nutritional supplements. Efforts are made to expand globally, with new production facilities being established to support this vision. Sustainability and social contribution are integrated into the corporate strategy to ensure a positive impact on society.
- Headquarters Seoul, South Korea
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website yuhan.co.kr
- Social Facebook Instagram
- Legal Name Yuhan Corporation
- Annual Revenue$1.52 B (USD)5.75as on Dec 31, 2025
- Net Profit$134.39 M (USD)174.56as on Dec 31, 2025
- EBITDA$120.81 M (USD)47.96as on Dec 31, 2025
- Investments & Acquisitions
Products & Services of Yuhan
Yuhan offers a comprehensive portfolio of products and services, including Rapicol Care Dry Syrup and Willopet.
A comprehensive cold medicine consumed like tea daily.
Customized nutritional supplements for dogs in varieties.
People of Yuhan
15 people are tracked at Yuhan (9 in leadership, 6 in team).
| Name | Role | Group |
|---|---|---|
Sewoong Oh | Executive Director/cso, R&d | Leadership |
Sujin Ahn | Executive Officer, Head Of Drug Metabolism And Pharmacokinetics | Leadership |
Calvin Huh | General Manager, New Product Development | Leadership |
Wonjoo Lee | General Manager | Leadership |
Yunjoo Kim | Director, Head Of Global BD | Leadership |
Wook Je Cho | Chief Executive Officer | Leadership |
Saeyoung Lee | Executive Director Of Medical Dpt | Leadership |
Lauren Young-Mi Lee | Evp, CTO Global R&d Inninnovation R&bd | Leadership |
Younggi Choi | Deputy Cso/head Of Drug Discovery/managing Director (중앙연구소 부소장/합성신약 부문장/전무) | Leadership |
Jeongweon Moon | CRM | Team |
Han Kim | Regional Representative For Europe | Team |
Jieon Lee | Clinical Science Manager | Team |
Jangwoo Shin | Senior Principal Scientist | Team |
Minyoung Park | R&bd Manager | Team |
Yerina Ji | Principal Scientist, R&d Strategy & Planning | Team |
Complete people profiles for Yuhan
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Yuhan
Yuhan is a publicly listed company on the KRX with ticker symbol 000100 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Nov 1962
- Listed onKRX: 000100
- Listed entityYuhan Corporation
- Exchange sectorHealth technology
- ISINKR7000100008
- Share price72,700.00 KRW (-0.14% on the day) · 2026-10-14
- Market capitalisation4,978,570,955,217.00 KRW
- Price to earnings22.9
- EPS (diluted, trailing year)3,171.12 KRW
- Dividend yield0.83%
- Volume (last session)183,660
Financials of Yuhan
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2,190.00B KRW | 194.08B KRW | 174.47B KRW |
| 2024 | 2,070.00B KRW | 70.69B KRW | 117.91B KRW |
| 2023 | 1,860.00B KRW | 136.20B KRW | 101.35B KRW |
| 2022 | 1,780.00B KRW | 95.14B KRW | 79.05B KRW |
| 2021 | 1,690.00B KRW | 102.58B KRW | 101.27B KRW |
Detailed financial statements for Yuhan
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Yuhan
Yuhan has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Waratnec.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Dental implant systems are developed and manufactured by Waratnec. | warantec.com | Seongnam-si, South Korea | 2001 | Jun 2017 | •••• |
Complete acquisition details for Yuhan
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Web traffic of Yuhan
Websites that share an audience with Yuhan (yuhan.co.kr).
Websites whose visitors overlap most with Yuhan. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ildong.com | 98% | 79.3K | #344,860 | View details | |
| samjinpharm.co.kr | 97% | 38.7K | #711,422 | View details | |
| chabio.com | 89% | 31.6K | #767,207 | View details | |
| ckdpharm.com | 85% | 89.5K | #398,415 | View details | |
| bukwang.co.kr | 73% | 142.7K | #395,152 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Yuhan
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Yuhan
Complete news archive for Yuhan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Yuhan
Yuhan is headquartered in Seoul, South Korea.
Annual revenue of Yuhan is $1.52B as on Dec 31, 2025.
Yuhan Corporation is involved in the development and production of pharmaceutical products and health solutions. The company operates in the healthcare sector, focusing on innovative drugs and consumer health products. Various solutions are offered, including comprehensive cold medicines and pet care nutritional supplements. Efforts are made to expand globally, with new production facilities being established to support this vision. Sustainability and social contribution are integrated into the corporate strategy to ensure a positive impact on society.
Yuhan offers Rapicol Care Dry Syrup and Willopet.
Yes, Yuhan is publicly traded on KRX under the ticker symbol 000100.
Yuhan has made 1 acquisition, including Waratnec.